Merck closes in on allergy trifecta with MK-8237 Phase IIb data
This article was originally published in Scrip
Executive Summary
With two new allergy drugs nearing potential US FDA approval, Merck & Co said its sublingual dust mite allergy immunotherapy MK-8237 cut nasal symptoms by up to 49% after 24 weeks of once-daily treatment in a Phase IIb clinical trial.